+
For instructor materials including Power Points, Answers to Clinical Encounter Questions, please contact userservices@mhprofessional.com.
++
Content Update
June 24, 2024
Pivmecillinam: A Newly Approved Penicillin Antibiotic: In April of 2024, the beta-lactam antibiotic, pivmecillinam, a prodrug of mecillinam, was approved by the United States Food and Drug Administration for the treatment of uncomplicated urinary tract infections in female adults 18 years of age and older.
++
Content Update
June 14, 2024
Ceftobiprole: A newly approved cephalosporin antibiotic: Effective treatment against bacterial infections is increasingly difficult as antimicrobial resistance is on the rise. Ceftobiprole medocaril, a 5th-generation cephalosporin, was recently approved by the U.S. Food and Drug Administration for the treatment of Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired pneumonia (CAP).
++
Content Update
December 21, 2023
Reacting to the Rise of Respiratory Syncytial Virus: An Update on Prevention: In 2023, the U.S. Food and Drug Administration (FDA) approved several prophylactic measures against the respiratory syncytial virus (RSV): 1) Nirsevimab (Beyfortus®) for the pediatric population; 2) a recombinant, adjuvanted RSVPreF3 vaccine (Arexvy®) for the geriatric population; and 3) a bivalent RSVpreF vaccine (Abrysvo®) for the pregnant and geriatric populations. Compared to palivizumab, the previous standard of care, nirsevimab has an extended half-life and convenient single-dosing schedule. Abrysvo® and Arexvy® are recommended by the Centers for Disease Control and Prevention (CDC) as single dose RSV vaccine options for adults 60 and older with shared decision making. Additionally, Abrysvo® is recommended in pregnant women at 32-36 weeks gestational age. Adverse effects (AEs) were mostly minor, although neurological AEs (e.g. Guillain-Barre syndrome) were noted in a small number of patients.
++
Content Update
February 22, 2023
Clinical Updates for Managing Methicillin-Resistant Staphylococcus aureus Bloodstream Infections in Adults: Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) are infections with notably high morbidity and mortality. High rates of persistent bacteremia and resource constraints have prompted practitioners to examine novel treatment modalities to improve patient outcomes. New literature has evaluated combination therapy with vancomycin or daptomycin with beta-lactam antibiotics as well as sequential long-acting lipoglycopeptides to facilitate early discharge in patients with MRSA BSI.
++
LEARNING OBJECTIVES
Upon completion of the chapter, the reader will be able to:
Describe how antimicrobials differ from other drug classes in terms of their effects on individual patients as well as on society as a whole.
Recognize that antimicrobial resistance is an inevitable consequence of antimicrobial therapy.
Identify guiding principles to consider when treating patients with antimicrobials, and apply these principles in patient care.
Differentiate between microbial colonization and infection based on patient history, physical examination, and laboratory and culture results.
Evaluate and apply drug-specific considerations when selecting antimicrobial therapy.
Evaluate and apply patient-specific considerations when selecting antimicrobial therapy.
Identify and apply principles of patient education and monitoring response to antimicrobial therapy.
Discuss causes of patients failing to improve while on ...